Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Deferred Taxes (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Deferred Taxes for 17 consecutive years, with -$10.9 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes fell 56.67% to -$10.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$66.3 million through Dec 2025, down 219.64% year-over-year, with the annual reading at -$66.3 million for FY2025, 219.64% down from the prior year.
  • Deferred Taxes hit -$10.9 million in Q4 2025 for Integra Lifesciences Holdings, down from -$8.7 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $10.7 million in Q4 2021 to a low of -$44.8 million in Q2 2025.
  • Historically, Deferred Taxes has averaged -$5.3 million across 5 years, with a median of -$3.3 million in 2021.
  • Biggest five-year swings in Deferred Taxes: surged 387.2% in 2022 and later tumbled 2331.18% in 2025.
  • Year by year, Deferred Taxes stood at $10.7 million in 2021, then tumbled by 156.07% to -$6.0 million in 2022, then tumbled by 146.48% to -$14.8 million in 2023, then soared by 52.94% to -$7.0 million in 2024, then crashed by 56.67% to -$10.9 million in 2025.
  • Business Quant data shows Deferred Taxes for IART at -$10.9 million in Q4 2025, -$8.7 million in Q3 2025, and -$44.8 million in Q2 2025.